CSIMarket Company Name, Ticker, Industry, else..
 
Enveric Biosciences Inc   (NASDAQ: ENVB)
 
Price: $1.4400 $0.00 0.000%
Day's High: $1.4700000286102295 Week Perf: 5.11 %
Day's Low: $ 1.37 30 Day Perf: -13.77 %
Volume (M): 42,933 52 Wk High: $ 13.25
Volume (M$): $ 0 52 Wk Avg: $3.83
Open: $1.47 52 Wk Low: $1.14



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 4
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Enveric Biosciences Inc. is a biotechnology company that focuses on developing and commercializing innovative therapies for patients suffering from cancer and other serious medical conditions. The company specializes in the research and development of cannabinoid-based pharmaceuticals, utilizing the therapeutic potential of cannabinoids to treat various symptoms and side effects of cancer treatments. Enveric Biosciences' goal is to improve the quality of life for patients by providing effective and safe treatments that address both physical and mental health aspects. The company is committed to conducting rigorous clinical trials and collaborating with healthcare professionals to bring their products to market.


   Company Address: 245 First Street Cambridge 2142 MA
   Company Phone Number: 444-8400   Stock Exchange / Ticker: NASDAQ ENVB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANRO        0.28% 
ARTL        841% 
ATXI        26.67% 
BFRG   -13.27%    
BTAI   -83.66%    
KTTA        4.58% 
• View Complete Report
   



Business Update

Neuroplastogens and Numbers Enveric Biosciences Strategic Leap in Intellectual Property amid Financial Shifts

Published Thu, Oct 16 2025 7:45 PM UTC

Cambridge, Mass. - Enveric Biosciences Patents Pathways to Mental Health Innovation In the dynamic intersection of biotechnology and psychiatry, Enveric Biosciences (NASDAQ: ENVB) stands as a forward-thinking entity, pioneering within the realm of neuroplastogenic therapeutics. Recently, the company celebrated a noteworthy stride in its strategic mission with the issuance of...
Business Update

Enveric Biosciences Secures $2.2 Million through Warrant Exercise to Advance Neuroplasticity-focused Innovations

Published Fri, Sep 19 2025 1:00 AM UTC

Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology firm based in Cambridge, Massachusetts, has successfully closed the exercise of certain outstanding warrants, resulting in gross proceeds of $2.2 million. This financial move is specifically tied to the exercise of Series A and Series B warrants, which enabled the purchase of up to a combined total of 2,424,998 shares...
Business Update

Advancements in Neuropsychiatric Therapeutics Enveric Biosciences Unveils Groundbreaking Bioproduction Techniques

Published Wed, Sep 17 2025 12:56 PM UTC

In an era marked by significant advancements in the field of medicinal chemistry, the ability to innovate bioproduction methods stands as a beacon of hope for drug discovery, particularly in the domain of neuropsychiatric disorders. Enveric Biosciences Inc. (NASDAQ: ENVB), a biotechnology enterprise based in Cambridge, Massachusetts, has recently garnered attention within th...
Business Update

In a strategic pivot aimed at enhancing its operational capacity and innovation potential, Enveric Bioscien...

Published Tue, Sep 2 2025 1:51 PM UTC

Enveric Biosciences: Pioneering Neuroplastogenic Therapeutics Amidst a Strategic Move to Cambridge In a strategic pivot aimed at enhancing its operational capacity and innovation potential, Enveric Biosciences (NASDAQ: ENVB), a visionary biotechnology company dedicated to advancing neuroplastogenic small molecules for psychiatric and neurological disorders, has announced the...
Business Update

Enveric Biosciences Achieves Preclinical Success with EB-003 Amid Financial Pressures,

Published Thu, Aug 28 2025 2:06 PM UTC

Enveric Biosciences Advances with EB-003 Amidst Financial Challenges Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company based in Cambridge, Massachusetts, is making strides in the realm of neuropsychiatric therapeutic development. Recently, the company announced a significant advancement with its lead candidate, EB-003, which targets neuropsychiatric indicatio...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 0.03
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.71
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.63
Working Capital Ratio 9.63
Leverage Ratio (MRQ) 0.11
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 47.67 $
Revenues (TTM) -
Cash Flow (TTM) 0.52 $
Cash 2.08 $
Book Value 2.03 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,454,841
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.